We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
REVIEW
Vitamin A (retinoids) regulation of mouse melanoma growth and differentiation.
Journal of Nutrition 2003 January
The incidence of melanoma is rapidly increasing in the U.S. population. At the present, there is no effective chemotherapy against invasive melanoma. At our laboratory, we have been studying retinoic acid (RA)-induced growth arrest and differentiation in the B16 murine melanoma cell model. Several immediate-early gene targets of RA were identified by gene arrays. In one of these genes, T-box binding protein-2 (Tbx-2), an RA response element, was identified in the promoter region that mediates the RA responsiveness of this gene. RA also induces a sixfold to eightfold increase in protein kinase C (PKC)alpha RNA and protein. This gene is not a direct target of RA but appears to be required for the biological effects of RA in B16 melanoma cells. PKC can alter gene transcription via phosphorylation of activator protein (AP)-1. RA increased AP-1 activity in B16 cells but with delayed kinetics compared with activation of PKC by phorbol dibutyrate. Clones stably expressing a dominant negative A-fos gene had reduced AP-1 activity and were less sensitive to RA induction of growth arrest and differentiation. Paradoxically, although inhibition of PKC enzyme activity blocked phorbol dibutyrate-stimulated AP-1 activity, it had no effect on RA-induced AP-1 activity. Further investigation showed that PKC enzyme activity was not required for RA-induced growth inhibition or stimulation of melanin synthesis. These data suggest that PKCalpha either works through a nonenzymatic protein-protein mechanism or may interfere with the enzymatic function of another isozyme of PKC to mediate the actions of RA in B16 melanoma cells.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app